Neogen Corp (NEOG)

$NEOG "Heads up alert! Upcoming earnings on Thursday, 10/9/2025 for $NEOG Bearish (3.2) Neogen Corporation: Financial Analysis Neogen Corporation, a key player in the food safety and animal diagnostics industry, has faced a turbulent period marked by significant financial and operational challenges. The company's trailing P/E ratio stands at an exorbitant 822.50, while the forward P/E is more reasonable at 16.00, suggesting expectations of improved earnings in the future. However, recent financial performance has been less than stellar, with the stock price dropping by 30.9% over the past six months to $5.80 per share. This decline reflects investor concerns over the company's ability to navigate current headwinds. The company's revenue growth has been hampered by integration challenges related to its acquisition of 3M's Food Safety Division, leading to reduced revenue guidance and profit margin pressures. Neogen's earnings per share (EPS) growth has also been under scrutiny, as recent reports indicate below-expected profitability. Comparatively, Neogen's financial metrics lag behind industry peers, who have reported more stable revenue streams and profitability margins. The recent announcement of the CFO's departure adds another layer of uncertainty to the company's financial stability and strategic direction, further unsettling investors. Additionally, class action lawsuits related to the alleged misleading of investors about the integration process have exacerbated concerns, impacting investor sentiment and stock valuation. Upcoming Earnings Report Insights Neogen is set to release its first-quarter earnings on October 9, 2025. This report will be critical in providing insights into the company's current financial health and future prospects. Historically, Neogen has faced volatility around earnings announcements, influenced by leadership changes and operational restructuring. Analyst consensus estimates suggest cautious optimism, with expectations of stabilization in revenue and potential improvements in profitability metrics. However, given the recent challenges, any deviation from expectations could significantly impact the stock's performance. Sector Performance Neogen operates within the broader life sciences and diagnostics sector, which has seen varied performance recently. The sector has been influenced by macroeconomic factors such as trade policy uncertainty and shifts in market sentiment towards technology and semiconductor stocks. While some companies within the sector have benefited from these trends, those with operational and integration challenges, like Neogen, have struggled to maintain investor confidence. Overall, the sector's performance has been mixed, with stability in certain areas offset by volatility in others, highlighting the importance of company-specific dynamics in determining stock performance. - Funds were net buyers of $NEOG during the previous reporting quarter. - Funds with large holdings in $NEOG include: - Last 10 days performance: 2% - Last 30 days performance: -1% - Last 90 days performance: 7% Some of the latest news articles: - Title: Neogen (NEOG): Buy, Sell, or Hold Post Q2 Earnings? Publication Date: 10/1/2025 4:03:41 AM, Source: yahoo URL: https://finance.yahoo.com/news/neogen-neog-buy-sell-hold-040341544.html?.tsrc=rss - Title: Neogen (NEOG) Stock Trades Up, Here Is Why Publication Date: 9/30/2025 4:51:29 PM, Source: yahoo URL: https://finance.yahoo.com/news/neogen-neog-stock-trades-why-165129526.html?.tsrc=rss - Title: Neogen® Renews Official Sponsorship with US Equestrian to Continue Advancing Equine Health Education Publication Date: 9/25/2025 9:26:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/neogen-renews-official-sponsorship-us-212600013.html?.tsrc=rss - Title: Neogen Corporation (NEOG) Slid Due to Below-Expected Revenue and Profitability Publication Date: 9/24/2025 1:06:09 PM, Source: yahoo URL: https://finance.yahoo.com/news/neogen-corporation-neog-slid-due-130609938.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."

Wall St is expecting 0.04 EPS for $NEOG Q1 [Reporting 10/09 BMO] http://www.estimize.com/intro/neog?chart=historical&metric_name=eps&utm_co

$RSVR Reservoir Media Trade Count: 20 | Total $: 1.7 K | 0.20 × 90-Day Avg $: 8.4 K | Call $: 1.6 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $NEOG Neogen Trade Count: 24 | Total $: 2.2 K | 0.07 × 90-Day Avg $: 29.8 K | Call $: 1.6 K | Put $: 595 | % Single-Leg: 76% | % Multi-Leg: 24% | % Contingent: – $ACTG Acacia Research Trade Count: 24 | Total $: 1.6 K | 0.26 × 90-Day Avg $: 6.3 K | Call $: 1.6 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $EHAB Enhabit Trade Count: 2 | Total $: 1.6 K | 0.45 × 90-Day Avg $: 3.6 K | Call $: 1.6 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –

$NEOG we going to pop soon or what? Anyone out there know what the big volume pop was at the close yesterday? Thanks!

Whiskey's Picks out tomorrow approx. 6:20 am PDT AH Gainers: $SONM $SOC $CDLX $AUPH $NEOG

CJS Securities has updated their rating for Neogen ( $NEOG ) to Market Perform with a price target of 10.

Russell 2000 (Healthcare) → $MDT Medtronic $MNKD MannKind $MRNA Moderna $MYGN Myriad Genetics $NEOG Neogen

Russell 2000 (Healthcare) → $MDT Medtronic $MNKD MannKind $MRNA Moderna $MYGN Myriad Genetics $NEOG Neogen

$NEOG Crushed on the monthly timeframe, but not a bad place to pick up some speculative calls 6+ months out, looks to be approaching a buy signal on the monthly timeframe. Relief rally?

$NEOG Massive adds (27 million worth) from institutions this month. Thank you for your attention to this matter. LOLLL